Stem Cell Research (Sep 2016)

Generation of an induced pluripotent stem cell line from a patient with chronic myeloid leukemia (CML) resistant to targeted therapies

  • G. Telliam,
  • O. Féraud,
  • F. Griscelli,
  • P. Opolon,
  • D. Divers,
  • A. Bennaceur-Griscelli,
  • A.G. Turhan

DOI
https://doi.org/10.1016/j.scr.2016.08.001
Journal volume & issue
Vol. 17, no. 2
pp. 235 – 237

Abstract

Read online

Chronic myeloid leukemia (CML) is a clonal malignancy initiated by the occurrence of a t (9;22) translocation, generating Ph1 chromosome and BCR-ABL oncogene in a primitive hematopoietic stem cell (HSC). The resistance of HSC to targeted therapies using tyrosine kinase inhibitors remains a major obstacle towards the cure. We have generated an iPSC line from a patient with CML using leukemic CD34+ cells cryopreserved at diagnosis. Ph1+ CML cells were reprogrammed by non-integrative viral transduction. These iPSCs harboured Ph1 chromosome and expressed pluripotency hallmarks as well as BCR-ABL. Teratoma assays revealed normal differentiation after injection in immunodeficient mice.